NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

Abstract Background Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour. For patients with inoperable disease, few treatment options are available after first line chemotherapy. The combination of ipilimumab and nivolumab has recently shown increased survival compared to standard ch...

Full description

Bibliographic Details
Main Authors: Vilde Drageset Haakensen, Anna K. Nowak, Espen Basmo Ellingsen, Saima Jamil Farooqi, Maria Moksnes Bjaanæs, Henrik Horndalsveen, Tine Mcculloch, Oscar Grundberg, Susana M. Cedres, Åslaug Helland
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Journal of Translational Medicine
Subjects:
Malignant pleural mesothelioma
Telomerase vaccine
Immunotherapy
hTERT
Nivolumab
Ipilimumab
Online Access:https://doi.org/10.1186/s12967-021-02905-3

Internet

https://doi.org/10.1186/s12967-021-02905-3

Similar Items